TORONTO, Feb. 28 /CNW/ - Spectral Diagnostics Inc. (TSX: SDI) today
announced that it will present new findings demonstrating the clinical utility
of its EAA(TM) Endotoxin Activity Assay, the only FDA cleared diagnostic for
the measurement of endotoxin, at the 12th Annual Critical Care for Endotoxemia
congress. The conference takes place in Fukuoka, Japan from February
28th-29th, 2008 and focuses on the role of endotoxemia in sepsis in critically
ill patients. The Company and a number of leading medical centres in Japan
including the Tokyo Medical Clinic, Osaka City General Hospital and Iwate
Medical University will each present findings using data collected with
Spectral's EAA(TM) product that highlight the clinical utility of the
diagnostic.
